HomeCompareFRAK vs JNJ

FRAK vs JNJ: Dividend Comparison 2026

FRAK yields 1.27% · JNJ yields 3.36%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 FRAK wins by $1.5K in total portfolio value
10 years
FRAK
FRAK
● Live price
1.27%
Share price
$157.50
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$21.5K
Annual income
$137.88
Full FRAK calculator →
JNJ
Johnson & Johnson
● Live price
3.36%
Share price
$147.50
Annual div
$4.96
5Y div CAGR
5.8%
Payout ratio
55%
After 10 yrs · $10,000 · DRIP
Portfolio value
$20.0K
Annual income
$827.78
Full JNJ calculator →

Portfolio growth — FRAK vs JNJ

📍 FRAK pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodFRAKJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, FRAK + JNJ cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
FRAK pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

FRAK
Annual income on $10K today (after 15% tax)
$107.94/yr
After 10yr DRIP, annual income (after tax)
$117.20/yr
JNJ
Annual income on $10K today (after 15% tax)
$285.83/yr
After 10yr DRIP, annual income (after tax)
$703.61/yr
At 15% tax rate, JNJ beats the other by $586.42/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of FRAK + JNJ for your $10,000?

FRAK: 50%JNJ: 50%
100% JNJ50/50100% FRAK
Portfolio after 10yr
$20.8K
Annual income
$482.83/yr
Blended yield
2.33%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

FRAK
No analyst data
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
+55.1% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

FRAK buys
0
JNJ buys
0
No recent congressional trades found for FRAK or JNJ in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricFRAKJNJ
Forward yield1.27%3.36%
Annual dividend / share$2.00$4.96
Payout ratio50%55%
1-year div growth0%4.2%
5-year div CAGR0%5.8%
Portfolio after 10y$21.5K$20.0K
Annual income after 10y$137.88$827.78
Total dividends collected$1.3K$5.6K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: FRAK vs JNJ ($10,000, DRIP)

YearFRAK PortfolioFRAK Income/yrJNJ PortfolioJNJ Income/yrGap
1← crossover$10,827$126.98$10,676$355.77+$151.00FRAK
2$11,713$128.49$11,407$389.39+$306.00FRAK
3$12,663$129.92$12,198$426.53+$465.00FRAK
4$13,681$131.26$13,056$467.62+$625.00FRAK
5$14,771$132.53$13,987$513.12+$784.00FRAK
6$15,939$133.73$14,998$563.56+$941.00FRAK
7$17,189$134.87$16,098$619.52+$1.1KFRAK
8$18,529$135.93$17,295$681.69+$1.2KFRAK
9$19,963$136.94$18,599$750.82+$1.4KFRAK
10$21,498$137.88$20,022$827.78+$1.5KFRAK

FRAK vs JNJ: Complete Analysis 2026

FRAKStock

The investment seeks to replicate as closely as possible, before fees and expenses, the price and yield performance of the MVIS® Global Unconventional Oil & Gas Index. The fund normally invests at least 80% of its total assets in securities that comprise the fund's benchmark index. The index contains companies that generate at least 50% of their revenues from unconventional oil and gas or that have properties with the potential to generate at least 50% of their revenues from unconventional oil and gas. The fund is non-diversified.

Full FRAK Calculator →

JNJHealthcare

Johnson & Johnson is a Dividend King with 62+ years of consecutive dividend increases. A healthcare conglomerate spanning pharmaceuticals, MedTech, and consumer health. JNJ spun off its consumer segment as Kenvue in 2023, focusing on higher-margin pharma and medical devices.

Full JNJ Calculator →
📬

Get this FRAK vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

FRAK vs SCHDFRAK vs JEPIFRAK vs OFRAK vs KOFRAK vs MAINFRAK vs ABBVFRAK vs MRKFRAK vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.